Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT04220866
Brief Title: Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

First Submitted : January 6, 2020
First Submitted that Met QC Criteria : January 6, 2020
First Posted : January 7, 2020

Last Update Submitted that Met QC Criteria : May 27, 2021
Last Update Posted : May 28, 2021